Diagnostic Visinin-like protein 1 (VLP-1) antibodies (anti-Visinin-like protein 1, anti-VLP-1) and antigens (recombinant Visinin-like protein 1 (VLP-1) protein) for Neurodegenerative diseases VLP-1 detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.

Cat:GMP-h-VLP-1
Awaiting product image
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
SKU GMP-h-VLP-1 Categories ,

For more than 100mg, click here for inquiry. >>

Product Details

Genemedi produces core diagnostic ingredients for test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome. GeneMedi offers paired diagnostics grade Visinin-like protein 1 (VLP-1) antibodies (monoclonal antibody, mab) and antigens for Neurodegenerative diseases (Alzheimer Disease(AD)) rapid test kit of Visinin-like protein 1 (VLP-1) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Neurodegenerative diseases (Alzheimer Disease(AD) ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control. Genemedi produces core diagnostic ingredients for test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome. GeneMedi offers paired diagnostics grade Visinin-like protein 1 (VLP-1) antibodies (monoclonal antibody, mab) and antigens for Neurodegenerative diseases (Alzheimer Disease(AD)) rapid test kit of Visinin-like protein 1 (VLP-1) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Neurodegenerative diseases (Alzheimer Disease(AD) ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.Visinin-like protein 1 (VLP-1, also known as VILIP-1) is a calcium-signaling molecule expressed in neurons. Meta-analysis of seven studies showed that VLP-1 in the cerebrospinal fluid is significantly higher in people with Alzheimer’s disease than in control subjects (effect size = 1.546, p <0.0001).

Product Description

Cat No. of Pruducts

GMP-h-VLP-1-Ag01

Product Name

Recombinant human Human VLP-1 Protein

Target

Visinin-like protein 1

Alias of Target/Biomarker

Expression platform

E.coli

Isotypes

Recombinant Antigen

Bioactivity validation

Visinin-like protein 1 (VLP-1) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in VLP-1 level test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome evaluation

Tag

His

Products description

Recombinant human Human VLP-1 Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.

Reconized/Reactive Species

Human

Purity

Purity: ≥95% (SDS-PAGE)

Application

positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at -20℃ to -110℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Genemeidi Omicron Variant Products
test
Previous slide
Next slide

Cat No. of Pruducts

GMP-h-VLP-1-Ab01,GMP-h-VLP-1-Ab02

Product Name

Anti-human Human VLP-1 mouse monoclonal antibody (mAb)

Target

Visinin-like protein 1

Alias of Target/Biomarker

HLP3, HPCAL3, HUVISL1, VILIP, VILIP-1, VSNL1

Expression platform

Hybridoma

Isotypes

Mouse IgG

Bioactivity validation

Human Visinin-like protein 1 (VLP-1) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Visinin-like protein 1 (VLP-1) antibodies in VLP-1 level test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome evaluation.

Tag

mFc

Products description

Anti-human Human VLP-1 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other Visinin-like protein 1 (VLP-1) antibodies.

Reconized/Reactive Species

Human

Purity

Purity: ≥95% (SDS-PAGE)

Application

ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at -20℃ to -111℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1

Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.